Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and
to determine the best dose which should be used to treat leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital